Crinetics Pharmaceuticals (CRNX) Shares Outstanding (2017 - 2026)

Crinetics Pharmaceuticals' Shares Outstanding (Entity) history runs 10 years deep, the most recent figure standing at $105.3 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 12.61% year-over-year to $105.3 million; the TTM figure through Mar 2026 stood at $105.3 million (up 12.61% YoY), while the FY2025 annual figure was $95.6 million, up 2.85% from the prior year.
• Shares Outstanding (Entity) for Q1 2026 stood at $105.3 million, up from $95.6 million in the prior quarter.
• The five-year high for Shares Outstanding (Entity) was $105.3 million in Q1 2026, with the low at $47.8 million in Q1 2022.
• The 5-year median for Shares Outstanding (Entity) is $78.5 million (2024), against an average of $74.6 million.
• The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Entity) gained 1.79% in 2023, then jumped 45.47% in 2024.
• Crinetics Pharmaceuticals' Shares Outstanding (Entity) stood at $53.9 million in 2022, then gained by 26.54% to $68.2 million in 2023, then surged by 36.31% to $92.9 million in 2024, then increased by 2.85% to $95.6 million in 2025, then rose by 10.19% to $105.3 million in 2026.
• Business Quant data shows CRNX's Shares Outstanding (Entity) at $105.3 million in Q1 2026, $95.6 million in Q4 2025, and $94.5 million in Q3 2025.